BioLamina, a leading provider of biologically relevant matrix proteins for stem cell culture, today announced a strategic collaboration with Cytochroma, a specialist in iPSC-derived cells for drug discovery and disease modelling. 

Cytochroma will incorporate BioLamina’s full-length, human recombinant laminin 521, into a new offering designed to support the generation, recovery, and expansion of iPSC-derived cells, including hepatocytes and cardiomyocytes. 

Cytochroma has used Biolaminin® since 2017, making the company one of BioLamina’s longest-standing partners. This new collaboration reflects a shared scientific commitment that precise control of the cellular microenvironment is a foundation for reproducible, scalable, and high-quality pluripotent stem cell workflows. 

“Cytochroma’s decision to incorporate LN521 directly into their product offering is a strong validation of the value full-length human laminins bring to advanced cell culture workflows. Researchers increasingly require robust and reproducible systems that function consistently from cell thawing to downstream applications. We’re proud that LN521 continues to play a central role in enabling best possible science for all kinds of workflows and purposes.” 

Dr Therése Kallur, Chief Scientific & Business Development Officer at BioLamina

BioLamina’s full-length laminins are designed to closely mimic the natural stem cell niche and recapitulate in vivo function in the laboratory, helping researchers achieve improved consistency, scalability, and biologically relevant outcomes across varied pluripotent stem cell applications. 

“We have built our iPSC-derived cell platform using Biolamina’s laminins, because consistent, high-quality cells start with a defined, biologically relevant matrix. Including LN521 directly in our offering gives our pharma and drug discovery customers a workflow they can trust, enhancing post-thaw recovery and improving the morphology of assay-ready cells. As the industry shifts toward human-relevant models that reduce reliance on animal testing, reproducibility at every step is what turns good biology into reliable data.” 

Dr Kate Cameron, Cytochroma Founder & CEO

The companies will jointly support the launch through coordinated marketing activities, scientific engagement, and conference collaborations throughout 2026. 

Background

About BioLamina 

BioLamina is a biotechnology company with deep expertise in matrix biology and cell culture. The company develops and manufactures laminin-based cell culture substrates that enable reliable growth and differentiation of pluripotent stem cells and other primary cells. 

By providing defined, high-quality and scalable cell culture solutions, BioLamina supports researchers and developers in advancing cell therapies and improving the accuracy of cell-based models used in drug discovery and development. 

Biolaminin® substrates are full-length, chemically defined and animal origin-free human recombinant laminins, designed for controlled cell culture systems and used in cell therapy development, including phase I–III clinical trials across major regulatory jurisdictions. BioLamina is headquartered in Stockholm, Sweden. 

About Cytochroma 

Cytochroma is a biotechnology company building genetically diverse human iPSC-derived cells and organoids for drug discovery, safety testing and disease modelling. Its models, including iPSC-hepatocytes and iPSC-cardiomyocytes, help pharmaceutical and AI drug discovery companies validate drug candidates and predict how real, varied human populations respond to a drug, years before clinical trials. The company has a particular focus on cardiometabolic disease, and developed assays predicting both drug efficacy and safety. 

Cytochroma has built one of the largest commercially available libraries of diverse iPSC donor lines, spanning sex, ancestry and genetic background. This library powers Wet AI™, Cytochroma’s data engine, which combines diverse human cell models to generate structured, AI-ready data to power AI based drug discovery. Cytochroma’s cells and data are used by top-tier pharmaceutical companies, contract research organisations and AI drug discovery partners worldwide. 

Built on more than a decade of stem cell and organoid research, Cytochroma is aligned with the global shift toward human-relevant models, supported by the FDA Modernization Act and the UK’s roadmap to phase out animal testing where validated alternatives exist. Cytochroma is headquartered in Edinburgh, UK. 

Press contacts:  

BioLamina: Elin Persson, Senior Marketing Manager | elin.persson@biolamina.com  

Cytochroma:  Dr Kate Cameron, Founder & CEO | kate@cytochroma.org